Analysts have been eager to weigh in on the Healthcare sector with new ratings on Schrodinger (SDGR – Research Report), Editas Medicine (EDIT – Research Report) and MacroGenics (MGNX – Research Report).
Schrodinger (SDGR)
In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on Schrodinger, with a price target of $33.00. The company’s shares closed last Wednesday at $31.37.
According to TipRanks.com, Schoenhaus is a 4-star analyst with an average return of
Schrodinger has an analyst consensus of Strong Buy, with a price target consensus of $44.83, which is a 38.8% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $42.00 price target.
See the top stocks recommended by analysts >>
Editas Medicine (EDIT)
In a report released yesterday, Gena Wang from Barclays maintained a Hold rating on Editas Medicine, with a price target of $11.00. The company’s shares closed last Wednesday at $11.07, close to its 52-week high of $11.91.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine with a $15.67 average price target, implying a 53.0% upside from current levels. In a report issued on February 27, J.P. Morgan also maintained a Hold rating on the stock with a $9.00 price target.
MacroGenics (MGNX)
In a report released today, Peter Lawson from Barclays maintained a Buy rating on MacroGenics, with a price target of $23.00. The company’s shares closed last Wednesday at $17.19, close to its 52-week high of $18.85.
According to TipRanks.com, Lawson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $17.20 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SDGR:
